A hospice-first, evidence-based clinical reference for clinicians, families, and patients navigating this diagnosis at end of life. Built for the team beside the bed.
Definition, mechanism, and the clinical reality of this diagnosis at end of life. What the hospice team needs to understand on day one.
End-stage HIV/AIDS with treatment failure represents the convergence of immunological devastation, uncontrolled opportunistic pathogen burden, metabolic collapse, and decades of living with a stigmatized diagnosis. The introduction of combination antiretroviral therapy (ART) in 1996 transformed HIV from a uniformly fatal diagnosis into a manageable chronic condition — people on effective ART now have life expectancy approaching that of the HIV-negative population. The patient dying from AIDS in 2024 is the patient for whom this pharmacological transformation has not succeeded: from multi-drug resistant HIV accumulated through years of incomplete viral suppression, from intolerance to the medications that could have maintained suppression, from social and structural barriers — poverty, housing instability, mental illness, substance use, incarceration — that made the daily discipline of ART adherence unsustainable, or from a late diagnosis after decades of unrecognized infection.[1][5]
The immunology of end-stage AIDS is defined by the CD4 count — the numerical measure of the immune system's capacity to defend against opportunistic pathogens that emerge below specific CD4 thresholds. Below 200: PCP, candidiasis, Kaposi's sarcoma. Below 100: cryptococcal meningitis, toxoplasma encephalitis, CMV disease, PML. Below 50: disseminated MAC, CMV retinitis, HIV-associated dementia. At CD4 below 25 with a detectable viral load, essentially no component of the adaptive immune system is functioning. The clinical consequence for the hospice patient is a chronic and progressive opportunistic pathogen burden producing daily fevers from MAC bacteremia, night sweats from the inflammatory response, diarrhea from MAC or CMV colitis or cryptosporidiosis, visual loss from CMV retinitis, cognitive impairment from HAND or CNS OIs, severe weight loss from wasting, and pain from peripheral neuropathy, Kaposi's sarcoma lesions, and OI-related pathology.[2][6]
The drug interaction complexity of a patient who may still be on ART while receiving comfort medications is the most specific and most dangerous clinical challenge in AIDS hospice. Protease inhibitors and some NNRTIs are powerful CYP3A4 and CYP2D6 inhibitors or inducers that dramatically alter blood levels of opioids, benzodiazepines, antiemetics, and antidepressants. The hospice clinician who treats end-stage AIDS as the disease of 1992 will miss the specific clinical realities of 2024 — a patient who may have been taking antiretrovirals for decades, whose medication regimen has a pharmacological complexity that exceeds any other hospice diagnosis, and whose social history may carry the weight of the entire AIDS epidemic.[7][8]
End-stage AIDS with treatment failure is not a single disease process — it is the simultaneous failure of the immune system on every front, producing a clinical picture in which multiple active infections, progressive wasting, neurocognitive decline, and extraordinary drug interaction risk converge in one patient. The hospice clinician entering this home must think in three simultaneous dimensions at every visit: (1) the opportunistic infection burden — which OIs are active, which are producing the most suffering, which are treatable for comfort; (2) the ART status — is the patient still on ART, and if so, what CYP450 interactions does that regimen create with every comfort medication being prescribed; (3) the human dimension — the stigma, the disclosure status, the survivor grief, and the decades of relationship with a disease that was once a death sentence and is now a death sentence again for this specific patient. No other hospice diagnosis requires all three of these dimensions to be held simultaneously at every clinical encounter.
Diagnostic workup, staging, and what to look for in hospice records. Most patients arrive with an established diagnosis — this section helps you read it.
Your loved one's medical team has already done the tests that established this diagnosis — often years ago. At hospice enrollment, we are not doing new diagnostic tests. We are reading the existing medical records carefully so we understand exactly where the illness stands, which infections are present, and which medications are helping with comfort. The numbers in the records — the CD4 count and the viral load — tell us how the immune system is functioning right now and help us plan the best comfort care. All of our focus is on keeping your person as comfortable as possible.
El equipo médico de su ser querido ya realizó las pruebas que establecieron este diagnóstico, a menudo hace años. Al inscribirse en hospicio, no estamos haciendo nuevas pruebas diagnósticas. Estamos leyendo cuidadosamente los registros médicos existentes para entender exactamente dónde está la enfermedad. Todo nuestro enfoque está en mantener a su ser querido lo más cómodo posible.
How HIV destroys the immune system, why treatment failed, and the health disparities that shaped this patient's trajectory. Relevant for family conversations and answering "why did this happen?"
Families often ask why their loved one got sick, and with HIV, this question carries a weight that is different from other diagnoses — because HIV has been wrapped in blame and judgment since the beginning of the epidemic. Here is what is true: HIV is a virus. It is transmitted through specific biological routes — sexual contact, shared needles, or from mother to child during birth or breastfeeding. It is not a moral failing. It is not a punishment. It is not the result of something your loved one did wrong. Millions of people around the world live with HIV and manage it successfully with medication. When the medication stops working — because the virus changed, because the side effects became unbearable, because life circumstances made taking daily pills impossible — the disease progresses. That is what happened here. Your loved one has been living with this illness, often for many years, and now the treatments that were available are no longer able to control it. None of this is anyone's fault. Your role now — and ours — is comfort, presence, and love.
When documenting the clinical history of an AIDS hospice patient, resist the framing of "noncompliance" as the explanation for treatment failure. The patient who accumulated resistance mutations across five drug classes over 15 years did so in a context: untreated depression that made daily pill-taking impossible during depressive episodes; housing instability that meant medications were lost or stolen; incarceration that interrupted ART for months at a time; side effects from older regimens (lipodystrophy, neuropathy, metabolic syndrome) that made continuation physically miserable; stigma that prevented engagement with HIV care. Document the structural context. It shapes your clinical relationship, your family communication, and your understanding of the human being you are caring for. The treatment failure is real. The reasons for it deserve to be understood, not judged.
What disease-directed treatments this patient may have received or may still be receiving. Understanding prior therapy helps anticipate complications and interpret the patient's trajectory.
The ART continuation decision at hospice enrollment is the most complex medication decision in AIDS hospice care — and it must be made explicitly, documented clearly, and communicated to every covering clinician. Unlike any other hospice diagnosis, the patient with end-stage AIDS may be on disease-directed therapy (antiretroviral medication) that serves a dual role: it is not curative, but even partially effective ART may reduce the frequency of opportunistic infection flares, slow wasting progression, and meaningfully reduce fever and night sweat burden. Stopping ART is not the default at hospice enrollment. Continuing ART is not the default either. The decision requires explicit clinical reasoning individualized to the patient's virological status, ART tolerability, drug interaction profile, and goals.[24][25]
Case 1 — Continue ART (partial suppression with comfort benefit): The patient whose current ART regimen partially suppresses the viral load — reducing it from, for example, 400,000 to 5,000 copies/mL — is deriving measurable immune benefit. Even incomplete suppression partially restores CD4 function and reduces the frequency of OI flares. This patient may have less fever, less wasting progression, and less OI burden than if ART is stopped entirely. If the regimen is tolerable (manageable GI side effects, acceptable pill burden) and the patient wants to continue, continuation is justified for comfort purposes. Document the comfort rationale: "ART continued for partial viral suppression and OI burden reduction — comfort-directed, not curative." Monitor for drug interactions with every comfort medication — especially if the regimen contains a boosted PI (ritonavir or cobicistat), which creates CYP3A4 inhibition affecting opioids, benzodiazepines, and multiple other comfort agents.[7][24]
Case 2 — Stop ART (fully failing regimen with intolerable burden): The patient whose ART is fully failing — viral load >100,000 copies/mL on the current regimen — and who is experiencing significant ART side effects (nausea, diarrhea, fatigue, metabolic toxicity) and who has decided to stop should have ART discontinued. Stopping simplifies the medication regimen, eliminates the drug interactions between ART agents and comfort medications (critically important for PI-boosted regimens), reduces GI side effects, and aligns with comfort-only goals. The viral rebound and immune decline after ART cessation occurs over weeks — not days — allowing time for symptom transition management. Document: the decision, the patient's informed participation, the rationale, and the expected virological trajectory. Communicate ART cessation to all covering clinicians and the hospice pharmacist.[24]
Case 3 — Palliative-intent ART (simplified regimen for symptom management): An intermediate approach that uses a partially effective, simplified ART regimen primarily for symptom management rather than viral cure. The INSTIs — dolutegravir and bictegravir — have the highest barrier to resistance and are the most likely to provide even limited benefit in a treatment-experienced patient. A palliative-intent regimen might consist of dolutegravir plus one tolerable NRTI backbone agent, with the explicit goal of partial suppression for OI burden reduction. This is analogous to the use of antifibrotics in IPF at hospice stage or palliative chemotherapy in oncology — disease modification repurposed as comfort. Document the palliative ART rationale explicitly: "Simplified ART regimen (dolutegravir-based) continued for partial immune reconstitution and symptom benefit — not for virological cure."[17][25]
Evidence-based criteria for continuing disease-directed therapy. This is not about giving up or holding on — it's about reading the data correctly.
The foundational clinical decision in AIDS hospice is not whether to treat — it is what treatment means in the context of a patient whose disease has exhausted curative options. Selwyn and Forstein's landmark work on palliative care integration in HIV demonstrated that concurrent comfort-focused and disease-modifying approaches improve symptom burden and quality of life even when virological cure is no longer achievable.[34] In end-stage HIV/AIDS with treatment failure, "therapy" is reframed: the goal is not viral suppression but symptom reduction, OI burden mitigation, and the preservation of whatever functional capacity remains. The ten criteria below define when disease-directed interventions remain consistent with comfort goals — when they are, in fact, comfort interventions wearing disease-directed clothing.
Knowing when treatment stops helping is not clinical failure. It is the most important clinical skill in this disease.
HIV/AIDS hospice has historically suffered from both extremes: patients referred too late after aggressive OI treatment in the final weeks, and patients whose comfort medications were prescribed without accounting for the ART drug interactions that altered every dose. Breitbart et al. documented that symptom burden in advanced AIDS patients is comparable to metastatic cancer — yet palliative care referral rates remain significantly lower, and hospice utilization in AIDS has been hampered by the complexity of concurrent ART and the emotional difficulty of stopping treatment in a disease with a 30-year history of fighting for access to treatment.[44] The scenarios below define when disease-directed interventions have crossed the line from comfort to burden.
The three drug interactions that will harm your patient tonight if you do not check: (1) PI-boosted regimen + midazolam = up to 13-fold increase in midazolam levels → respiratory depression. Oral midazolam is contraindicated; parenteral only at 25–50% dose. (2) PI-boosted regimen + fentanyl = 2–3-fold increase in fentanyl levels → start at 50% of standard dose or use morphine/hydromorphone instead. (3) Efavirenz or ritonavir + methadone = 50–60% reduction in methadone levels → patient is in opioid withdrawal that looks like disease symptoms. These interactions are documented, predictable, and preventable. Check hiv-druginteractions.org before every comfort medication prescription. Post the patient's specific interaction profile on the medication list, in the comfort kit instructions, and in every covering clinician handoff. The covering nurse at 2 AM who reaches for the comfort kit must know these dose adjustments before they draw up the medication.[40]
Evidence-graded integrative, interventional, and complementary approaches. Grade A = RCT; B = multi-observational/meta-analysis; C = limited clinical, strong preclinical; D = expert opinion.
Evidence grading, dosing where supported, drug interaction flags, and explicit contraindications specific to this diagnosis. Patients will use supplements — this section helps you have the right conversation.
| Herb / Supplement | Evidence Grade | Typical Dose | Potential Benefit | ⚠ Interactions / Contraindications |
|---|---|---|---|---|
| Melatonin | Grade C | 1–5 mg PO 30–60 min before bedtime; start at 1 mg, titrate to effect | Sleep disruption and circadian dysregulation are among the most prevalent and least treated symptoms in HIV at all stages. HIV-related insomnia is driven by neuroinflammation, circadian disruption from wasting-associated cortisol dysregulation, psychological hyperarousal from PTSD in long-term survivors, and medication side effects. Melatonin may improve sleep onset latency and sleep quality with a favorable safety profile.[55] | Minimal CYP450 interactions — melatonin is primarily metabolized by CYP1A2 with minor CYP2C19 involvement. Low interaction risk with most ART agents. Fluvoxamine (CYP1A2 inhibitor) significantly increases melatonin levels — unlikely in this population. Safe to use with PI-boosted regimens. Avoid sustained-release formulations if hepatic impairment is present. May cause morning drowsiness — titrate carefully in patients with HAND. |
| Probiotics (Lactobacillus, Bifidobacterium, Saccharomyces boulardii) | Grade B | Lactobacillus/Bifidobacterium multi-strain: 10–20 billion CFU daily; Saccharomyces boulardii: 250–500 mg BID | Multiple clinical studies in HIV-positive patients demonstrate that probiotics reduce the frequency and severity of diarrhea (both ART-related and HIV enteropathy-related), improve gut mucosal integrity, and may reduce systemic immune activation markers (IL-6, sCD14). The Irvine et al. and d'Ettorre et al. studies showed improved GI symptoms and reduced microbial translocation markers in HIV patients on ART.[56] | Critical safety concern in severe immunosuppression: Live bacterial and fungal probiotics carry a theoretical risk of bacteremia or fungemia in patients with CD4 <50 and compromised gut mucosal barrier. Lactobacillus bacteremia and Saccharomyces fungemia have been reported in severely immunocompromised patients (primarily transplant and ICU populations). Use pharmaceutical-grade products from reputable manufacturers to minimize contamination risk. Monitor for fever after initiation. Consider discontinuing if CD4 falls below 20 or if the patient develops new fevers of unclear etiology. No significant CYP450 interactions with ART. |
| L-Glutamine | Grade C | 10–30 g PO daily, divided BID-TID; mix powder in water or food; start at 10 g daily and titrate | L-glutamine is the primary fuel source for enterocytes and plays a critical role in maintaining gut mucosal integrity. In HIV, the chronic enteropathy that produces malabsorption, diarrhea, and bacterial translocation is partly driven by glutamine depletion from chronic immune activation. Small clinical studies (Noyer et al., Shabert et al.) suggest that glutamine supplementation may improve intestinal permeability, reduce diarrhea frequency, and support lean body mass maintenance in HIV wasting.[57] | No significant drug interactions with ART agents. Generally well tolerated. May cause mild bloating or flatulence at higher doses. Caution in patients with hepatic encephalopathy (glutamine is converted to glutamate and ammonia). Avoid in patients with severe hepatic dysfunction (hepatitis B/C co-infection with decompensated cirrhosis — common in the HIV population). Use pharmaceutical-grade powder — quality control is critical for immunocompromised patients. |
| Omega-3 Fatty Acids (EPA/DHA) | Grade C | 1–3 g combined EPA/DHA daily (fish oil capsules or liquid); pharmaceutical-grade products preferred | Omega-3 fatty acids have anti-inflammatory properties that may modulate the chronic immune activation driving HIV wasting and systemic inflammation. Clinical studies in HIV patients demonstrate reduction in triglycerides (commonly elevated by PI-based ART), potential reduction in inflammatory markers (CRP, IL-6), and modest improvement in body composition. May also provide benefit for the depressive symptoms common in advanced HIV through neuroinflammatory modulation.[58] | Minimal CYP450 interactions — safe with most ART regimens. Fish oil may increase bleeding risk at high doses (>3 g/day) in patients on anticoagulants or with thrombocytopenia (common in advanced AIDS). May cause fishy taste, GI upset, or diarrhea — start at lower doses in patients with existing GI symptoms. Use pharmaceutical-grade products (USP verified) to minimize mercury and PCB contamination — particularly important in immunocompromised patients. Refrigerate to prevent oxidation. |
| Vitamin D (Cholecalciferol, D3) | Grade B | 1,000–4,000 IU daily PO; higher loading doses (50,000 IU weekly × 8–12 weeks) for documented severe deficiency (<10 ng/mL) then maintenance | Vitamin D deficiency is present in 60–85% of HIV-positive patients and is exacerbated by ART (particularly efavirenz and tenofovir), dark skin pigmentation (the majority of patients with advanced AIDS in the US are Black or Hispanic), chronic illness, and limited sun exposure. Deficiency contributes to bone loss, muscle weakness, fatigue, and immune dysfunction. Multiple studies (Eckard et al., Havens et al.) demonstrate that vitamin D supplementation improves 25(OH)D levels, bone mineral density, and may reduce systemic inflammation in HIV patients.[59] | Efavirenz accelerates vitamin D catabolism via CYP24A1 induction — patients on efavirenz may require higher maintenance doses. Minimal CYP3A4 interaction with PIs at standard supplementation doses. Monitor 25(OH)D levels if available. Hypercalcemia risk is extremely low at standard doses but monitor if the patient has granulomatous OIs (MAC, histoplasmosis) which can cause autonomous 1,25(OH)D production. Safe to use with all ART classes at standard doses. |
| Turmeric / Curcumin | Grade C | Curcumin extract 500–1,000 mg BID with food and black pepper (piperine) for absorption; turmeric spice in food as tolerated | Curcumin has demonstrated anti-inflammatory, antioxidant, and immunomodulatory properties in preclinical HIV studies, including inhibition of NF-κB (a key mediator of HIV transcription and immune activation), reduction of TNF-α, and in vitro anti-HIV activity. Limited clinical data in HIV patients specifically, but anti-inflammatory benefit is plausible for the chronic immune activation driving wasting and systemic inflammation.[60] | Significant drug interaction concern: Curcumin inhibits CYP3A4, CYP2C9, CYP1A2, and P-glycoprotein in vitro. In patients on PI-boosted regimens (already CYP3A4-inhibited), adding curcumin creates unpredictable additive enzyme inhibition that could increase levels of opioids, benzodiazepines, and other CYP3A4 substrates. Piperine (black pepper extract, commonly added to curcumin supplements for bioavailability) is itself a CYP3A4 inhibitor that further compounds the interaction risk. Use turmeric in food (low bioavailability, minimal interaction risk) rather than concentrated curcumin supplements with piperine. If curcumin supplements are used, check hiv-druginteractions.org and use without piperine. |
| Medical Marijuana / CBD | Grade B | CBD oil/tincture: 10–25 mg BID, titrate to 25–50 mg BID; THC:CBD balanced products: start 2.5 mg THC / 2.5 mg CBD; whole-plant products via vaporization (not smoking) PRN | Cannabis and CBD have multi-RCT and large observational study support for appetite stimulation, nausea reduction, neuropathic pain, insomnia, and anxiety in HIV/AIDS patients. Abrams et al. demonstrated that inhaled cannabis improved caloric intake and reduced neuropathic pain in HIV patients. CBD specifically may provide anti-inflammatory and anxiolytic benefit without psychoactive effects — valuable for patients with HAND who cannot tolerate THC-related cognitive effects.[50] | THC and CBD are CYP3A4 and CYP2C9 substrates; PI-boosted regimens may increase THC/CBD levels and effects — start at lower doses in patients on ritonavir or cobicistat. CBD inhibits CYP2C19 and CYP3A4 and may increase levels of some ART agents (check interaction). Infection precaution: Do not smoke cannabis — fungal contamination (Aspergillus) in plant material poses a serious risk of invasive aspergillosis in patients with CD4 <50. Vaporization at high temperature or edible/tincture forms are safer. Use regulated dispensary products with quality testing where available. State legality varies — document medical recommendation in the clinical record. |
A guide, not a prediction. Every patient's trajectory is shaped by CD4 nadir, dominant opportunistic infections, ART history, wasting severity, neurocognitive status, and social support.
The trajectory of end-stage AIDS with treatment failure is unlike any other hospice diagnosis. It is not a single linear decline — it is a chronic baseline deterioration punctuated by acute opportunistic infection flares, each of which depletes physiological reserve and accelerates the underlying wasting and immune collapse. The patient with disseminated MAC and daily fevers follows a different functional path than the patient with CMV retinitis and progressive blindness, or the patient with PML and rapid neurological decline. Wasting is continuous and progressive without effective ART, driven by chronic immune activation, TNF-α elevation, and the metabolic demands of recurrent infections. HIV-associated neurocognitive disorder (HAND) may add cognitive decline to the physical burden at any point. The timeline below must be read through the lens of the patient's specific OI burden, their CD4 trajectory, whether ART has been continued on a palliative basis, and the accumulated physiological toll of what may be decades of living with HIV. No two AIDS deaths look the same — but the pattern of OI-punctuated decline with progressive wasting is the unifying clinical signature.[63]
Symptom-targeted pharmacology for end-stage HIV/AIDS with treatment failure. Every comfort medication must be checked against the ART regimen before prescribing. The drug interaction complexity of this diagnosis exceeds any other in hospice medicine.
The dominant symptom drivers in end-stage AIDS are fever and night sweats from disseminated OIs (especially MAC), wasting-driven cachexia and anorexia, neuropathic pain from HIV peripheral neuropathy, dyspnea from recurrent PCP or pulmonary disease, and the cumulative pain burden of advanced illness. The overriding pharmacological challenge is that every comfort medication must be cross-referenced against the patient's antiretroviral regimen — the CYP3A4, CYP2D6, and UGT1A1 interactions of PIs, NNRTIs, and pharmacoenhancers (ritonavir, cobicistat) alter the blood levels of opioids, benzodiazepines, antiemetics, antidepressants, and antifungals in ways that can produce fatal toxicity or therapeutic failure at standard doses.[72]
AIDS medication management at hospice enrollment has a single non-negotiable safety rule: CHECK THE HIV DRUG INTERACTION DATABASE (hiv-druginteractions.org) BEFORE PRESCRIBING ANYTHING. The CYP3A4, CYP2D6, and UGT1A1 interactions of antiretroviral medications with comfort medications are severe, well-documented, and have caused iatrogenic harm and death in patients receiving standard doses of comfort medications that were safe in all other hospice patients. This check takes 30 seconds and it is mandatory.[72]
Rule 2: Document the interaction check in the clinical note for every new comfort medication prescription. Write: "Checked hiv-druginteractions.org — [result]."
Rule 3: If the ART regimen is a PI-boosted regimen (any regimen containing ritonavir or cobicistat), start ALL opioids and benzodiazepines at 25–50% of the standard starting dose and titrate slowly. Boosted PIs are potent CYP3A4 inhibitors that can increase midazolam levels 5-fold, fentanyl levels 3-fold, and oxycodone levels 2–3-fold. Standard hospice doses in these patients are overdoses.[73]
| Drug | Class / Target Symptom | Starting Dose | Notes / Cautions |
|---|---|---|---|
| Azithromycin | Macrolide / MAC treatment & prophylaxis | 500 mg PO daily | The most important comfort medication in advanced AIDS. Dramatically reduces fever and night sweats from disseminated MAC — often within 1–2 weeks. Combine with ethambutol 15 mg/kg daily for active MAC treatment. Mild CYP3A4 inhibitor — manageable interaction with most ART. ⚠ QTc prolongation — monitor ECG if combining with fluconazole or ondansetron.[74] |
| Fluconazole | Antifungal / Cryptococcal prophylaxis & candidiasis | 200 mg PO daily | Cryptococcal meningitis secondary prophylaxis and oropharyngeal/esophageal candidiasis treatment. CYP3A4, CYP2C9, and CYP2C19 inhibitor — increases blood levels of many medications including certain PIs. Check interaction with current ART specifically. Continue throughout hospice unless oral route lost in final days.[74] ⚠ QTc prolongation with azithromycin — obtain baseline ECG. |
| TMP-SMX DS | Antibiotic / PCP prophylaxis | 1 DS tab PO daily | PCP prophylaxis — continue if tolerated and patient has had PCP or CD4 <200. Most important OI prophylaxis in AIDS. Well-tolerated in most patients. Discontinue only in final days when oral route lost or if causing significant adverse effects (rash, cytopenias). Minimal ART interactions.[74] |
| Megestrol acetate | Progestin / HIV wasting & anorexia | 800 mg PO daily | FDA-approved for AIDS-related anorexia and cachexia. Stimulates appetite and may produce modest weight gain (primarily fat, not lean mass). ⚠ Do NOT stop abruptly after >4 weeks — suppresses adrenal cortisol; taper over 1–2 weeks to avoid adrenal crisis. Increases VTE risk. Minimal direct ART interactions.[75] |
| Dronabinol | Cannabinoid / Anorexia & nausea | 2.5 mg PO BID–TID | FDA-approved for AIDS-related anorexia and chemotherapy-related nausea. Adjunct to megestrol for combined anorexia/nausea. Start low — CNS effects (dizziness, euphoria, somnolence) may be pronounced in debilitated patients. CYP2C9/3A4 substrate — check interaction with PI-boosted regimens; ritonavir may increase dronabinol levels.[75] |
| Testosterone cypionate | Androgen / Hypogonadism & wasting | 200 mg IM q2 weeks | HIV-associated hypogonadism is common and contributes to wasting, fatigue, depression, and loss of lean body mass. Check morning testosterone level if not recent. Replaces deficient testosterone — improves lean mass, energy, and mood. Monitor hematocrit (erythrocytosis risk). Minimal direct ART interactions.[76] |
| Gabapentin | Anticonvulsant / HIV peripheral neuropathy | 100–300 mg PO TID, titrate | First-line for HIV distal sensory polyneuropathy — burning feet, numbness, allodynia. Start low and titrate over 1–2 weeks to 300 mg TID or higher as tolerated. Renally cleared — not CYP-metabolized, so minimal ART interactions (advantage over pregabalin in complex ART regimens). Dose-adjust for renal impairment. Somnolence and dizziness common at initiation.[77] |
| Morphine | Opioid / Pain & dyspnea | 2.5–5 mg PO/SQ q4h | First-line opioid for pain and dyspnea. Primarily glucuronidated (UGT2B7) — less affected by CYP3A4 inhibition than fentanyl or oxycodone, making it a safer choice with PI-boosted regimens. ⚠ REDUCE DOSE 50% if on PI-boosted regimen (ritonavir/cobicistat) — PIs inhibit UGT pathways and P-glycoprotein, increasing morphine exposure. Titrate to effect. Renal dose adjustment needed.[73] |
| Hydromorphone | Opioid / Pain (alternative) | 0.5–1 mg PO/SQ q4h | Alternative opioid — primarily glucuronidated (UGT), safer CYP interaction profile than fentanyl with PI-boosted regimens. Preferred over fentanyl in patients on ritonavir/cobicistat. Reduce dose 50% with PI-boosted ART and titrate. More potent than morphine (approximately 4:1 PO ratio). Useful when morphine is not tolerated or renal function is impaired.[73] |
| Methadone | Opioid / MOUD & pain | Per MOUD protocol or pain titration | If patient is on MOUD: ⚠ CHECK ART INTERACTIONS IMMEDIATELY — efavirenz reduces methadone levels 50% via CYP3A4 induction (causes opioid withdrawal); ritonavir reduces methadone levels 36%. Contact methadone clinic to discuss. If using for pain: complex pharmacology — long QTc risk, accumulation, CYP3A4/2B6/2D6 substrate. Requires ART-specific dose adjustment. Document interaction and management plan.[78] |
| Lorazepam | Benzodiazepine / Anxiety | 0.5 mg PO/SQ q4–6h PRN | Glucuronidated (UGT) — less CYP3A4 interaction than midazolam or diazepam, making it the preferred benzodiazepine with PI-boosted ART. ⚠ REDUCE DOSE if on PI-boosted regimen — PIs inhibit UGT pathways. Start at 0.5 mg (not 1 mg) in patients on ritonavir/cobicistat. Useful for anxiety, agitation, and adjunctive seizure management. SQ route available when oral fails.[73] |
| Midazolam | Benzodiazepine / Terminal agitation | 1–2.5 mg SQ PRN | ⚠ CONTRAINDICATED ORAL ROUTE with PI-boosted regimens — oral midazolam undergoes extensive first-pass CYP3A4 metabolism; ritonavir increases oral midazolam AUC 13-fold. IV/SQ route bypasses first-pass but still affected — use at 25–50% of standard dose with extreme caution in patients on ritonavir/cobicistat. Have drawn and labeled at bedside for terminal agitation and catastrophic symptoms. For seizures from CNS OIs.[73] |
| Mirtazapine | Antidepressant / Depression + insomnia + anorexia | 7.5–15 mg PO QHS | Triple benefit in AIDS: antidepressant effect, appetite stimulation (antihistaminic), and sleep improvement. Start at 7.5 mg — lower doses are more sedating (paradoxical dose-response for sedation). CYP3A4/1A2/2D6 substrate — check interaction with PIs (ritonavir may increase levels). Particularly useful when depression, insomnia, and wasting coexist. Weight gain effect is therapeutic in this population.[79] |
| Ondansetron | 5-HT3 antagonist / Nausea | 4 mg PO/IV q8h | First-line antiemetic for nausea from OIs, ART, or disease progression. CYP3A4/1A2/2D6 substrate — PIs may increase levels modestly. ⚠ QTc prolongation — assess additive risk with azithromycin and fluconazole; obtain baseline ECG if using all three simultaneously. ODT formulation available for patients with dysphagia.[79] |
| Loperamide | Antidiarrheal / HIV-related diarrhea | 2 mg PO after each loose stool (max 16 mg/day) | HIV enteropathy and OI-related diarrhea (cryptosporidiosis, MAC, CMV colitis) are major sources of discomfort and wasting acceleration. Loperamide is first-line symptomatic management. P-glycoprotein substrate — ritonavir inhibits P-gp and may increase systemic loperamide absorption (normally minimal). At standard doses, this interaction is rarely clinically significant. Avoid exceeding maximum dose.[79] |
| Glycopyrrolate | Anticholinergic / Terminal secretions | 0.2 mg SQ q4h PRN | Reduces terminal secretions without CNS effects — preferred over hyoscine/scopolamine in patients with HAND or delirium (does not cross blood-brain barrier). Quaternary ammonium compound with minimal CYP metabolism — no significant ART interactions. Have drawn and labeled at bedside before the final phase. Also useful for excessive salivation and drooling.[71] |
Before the crisis — not during it. The following must be pre-drawn, labeled, and at the bedside with written instructions for families and covering nurses. All doses below assume NO PI-boosted ART regimen. If on ritonavir/cobicistat: reduce opioid and benzodiazepine doses by 50% and label accordingly.
PCP dyspnea crisis / respiratory failure: Morphine 2.5–5 mg SQ — drawn and labeled "For breathing difficulty — give SQ and call nurse." Repeat q15min if no relief (max 3 doses before calling clinician).
Seizure from CNS OI (toxoplasmosis, PML, cryptococcal): Midazolam 1–2.5 mg SQ — drawn and labeled "For seizure — give SQ and call 911/nurse." If on PI-boosted ART: use 0.5–1 mg. Alternative: rectal diazepam 10–20 mg.
Terminal agitation / severe restlessness: Midazolam 1–2.5 mg SQ PRN q30min. Lorazepam 0.5–1 mg SQ q4h PRN. Label clearly with dose adjustments if on PI-boosted regimen.
Terminal secretions / noisy breathing: Glycopyrrolate 0.2 mg SQ q4h — drawn and labeled. "For noisy breathing — give SQ. This reduces fluid buildup. It does not treat pain."
Fever crisis / rigors: Acetaminophen 650 mg PR (rectal suppository) if oral route lost. Cool cloths. Call nurse if temp >103°F with rigors.
Nausea / vomiting (oral route lost): Ondansetron 4 mg SL/IV or promethazine 25 mg PR.
High-yield clinical pearls for the hospice team caring for end-stage AIDS. The drug interactions, the disclosure complexity, the OI management — the things that make this diagnosis unlike any other in hospice medicine.
AIDS crisis bereavement, HIV stigma and disclosure, sexuality and gender identity, and goals-of-care communication. The psychosocial burden that has shaped this patient's entire life — not just their dying.
The psychosocial burden of end-stage HIV/AIDS is unlike any other diagnosis in hospice medicine. The patient dying from AIDS in 2026 carries a grief history that may span four decades — a history of catastrophic loss, chronic stigma, social isolation, healthcare distrust, and the specific psychological weight of having survived an epidemic that killed most of their peers. Depression affects 40–60% of people with HIV — roughly double the rate in other terminal diagnoses — and is compounded by HIV-associated neurocognitive disorder, chronic pain, social isolation from disclosure fears, and the cumulative trauma of repeated loss.[81] Anxiety, PTSD, and substance use disorders co-occur at rates that dwarf the general hospice population. The hospice clinician who treats the psychosocial dimension of AIDS as equivalent to any other terminal diagnosis has missed the clinical reality entirely.
This patient's psychological suffering did not begin with their hospice admission. It began with their HIV diagnosis — which may have been a death sentence when it was delivered. It continued through decades of stigma, medication burden, disclosure anxiety, and the progressive loss of people who understood what they were living through. The hospice team's role is not to fix this history. It is to witness it, to assess its clinical impact on the dying process, and to connect the patient with spiritual and psychological support that is specific to what they have endured.[82]
The long-term HIV survivor who has been positive since the 1980s or 1990s has experienced one of the most catastrophic series of losses in the history of American epidemics. This grief is specific, documented, and clinically significant.[83]
The psychological profile of the long-term HIV survivor entering hospice is shaped by specific experiences that no other patient population shares:[85]
HIV stigma in 2026 is reduced but not gone. It remains the primary barrier to social support, healthcare engagement, and psychological well-being for many people with HIV — and it intensifies at end of life when the patient's capacity to control information diminishes.[87]
HIV disclosure at end of life creates clinical, legal, and relational complexities that no other diagnosis produces:[89]
HIV disproportionately affects sexual and gender minority communities, and the end-of-life needs of these patients require specific clinical competence:[91]
The intersection of HIV, culture, and religion creates specific end-of-life dynamics that the hospice team must navigate with awareness and sensitivity:[93]
"Ask about the AIDS crisis. Specifically. By name. 'Were you affected by the AIDS crisis in the 1980s and '90s?' If the answer is yes, clear your schedule. What comes next is the most important clinical conversation you will have with this patient. It is the grief history that explains the hypervigilance, the distrust, the exhaustion, and the look in their eyes that you couldn't quite place. You are not their therapist. You are their witness. That is enough — and it is everything."
Plain language for families. Share, print, or read aloud at the bedside.
You are watching someone you love go through something that is hard to see. The fevers, the weight loss, the fatigue — these are part of a serious illness that has been affecting their immune system for a long time. The medical team is focused on keeping your person comfortable, managing every symptom that can be managed, and making sure they are not suffering unnecessarily. You are part of this team. Your presence, your voice, your touch — these matter more than you know, and the things you can do at the bedside are real and important. This guide will help you understand what you may see in the days and weeks ahead, and what you can do to help.[95]
Usted está acompañando a alguien que ama a través de algo difícil de presenciar. Las fiebres, la pérdida de peso, la fatiga — son parte de una enfermedad seria que ha estado afectando su sistema inmunológico por mucho tiempo. El equipo médico está enfocado en mantener cómoda a su persona, manejando cada síntoma que pueda ser manejado. Usted es parte de este equipo. Su presencia, su voz, su toque — importan más de lo que sabe.
A fever above 101°F that does not come down with medication within one hour. Any sudden change in vision — blurriness, dark spots, or loss of part of the visual field. A sudden change in mental status — new confusion, difficulty speaking, inability to recognize you, or unusual drowsiness that is different from normal fatigue. A seizure of any kind. Severe headache with stiff neck (could indicate a treatable brain infection). Difficulty breathing or breathing that looks like work — using stomach or neck muscles to breathe. Blood in vomit, stool, or urine. A new rash that is spreading rapidly or looks like blisters. Severe diarrhea — more than six loose stools in a day or any bloody diarrhea. Falls or inability to stand that is new. Any medication that was accidentally skipped or doubled — call before giving the next dose, because the drug interactions in this illness make dosing errors more dangerous than in most other conditions.
🙏 Research shows that patients who have consistent family presence at the bedside have better pain control, less anxiety, and greater peace in their final days. You are not a spectator — you are part of the care team. The things you do — the cool cloth, the hand-holding, the quiet presence — are therapeutic interventions that no clinician can replicate. You are enough. And when you need help, call us — that is what we are here for.
Clinical field wisdom from 12+ years at the bedside. The things you learn after doing this long enough. Not guidelines — real.
Peer-reviewed citations. Based on articles retrieved from PubMed. All PMIDs hyperlinked. Evidence levels assigned by article type.
terminal2.care content is for educational purposes and is not a substitute for clinical judgment. Based on articles retrieved from PubMed. © Terminal2 | terminal2.care
Session notes — not saved to any server. Clears when you close the tab.
Use this space for visit notes, clinical reminders, or patient-specific observations. This text is stored only in your browser session.